ATR

AptarGroupA

NYSE / Materials

At close

2026-07-18

Current thesis

Reported Q1 sales rose 11%, injectables grew 20%, Beauty core sales grew 3%, and management guided to Q2 adjusted EPS of $1.32-$1.40 with growth expected across segments outside emergency medicine. [#SEC-8K-2026-04-30]

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +8.7.

What can break

Analyst target count, estimate revisions, options data, short interest and direct operating peers are unavailable.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $140.00 · Bull $165.67 · Bear $112.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-07-18 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade A · Constructive

Confidence Medium · Net Neutral

Target $165.67

Why

Momentum84 · Δ7d +8.7

Value56 · Δ7d -0.9

Sentiment54 · Δ7d -

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

+8.7

Δ21d

+40.4

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.9

Δ21d

-1.6

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

Δ21d

Why this grade

Composite grade A. Momentum 83.9 / Value 55.8 / Sentiment 54.2

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$8.46B

Beta

0.48

Shares Out

63.82M

P/E (TTM)

19.7

P/S (TTM)

2.20

P/FCF (TTM)

43.19

Rev YoY

+10.8%

EPS YoY

-4.0%

Gross Margin

+29.0%

Op Margin

+14.8%

Net Debt

$1.14B

Current Ratio

1.66

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology